Recently, increasing numbers of prospective phase II/III clinical trials have reported positive results with neoadjuvant chemotherapy combined with PD-1/PD-L1 inhibitors compared with chemotherapy or immunotherapy alone in resectable NSCLC (1–5). The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.